Paul Josephs's most recent trade in Lifecore Biomedical Inc was a trade of 150,000 Performance-Based Restricted Stock Units done . Disclosure was reported to the exchange on July 8, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Lifecore Biomedical Inc | Paul Josephs | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jul 2025 | 150,000 | 1,350,000 | - | - | Performance-Based Restricted Stock Units | |
| Lifecore Biomedical Inc | Paul Josephs | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jul 2025 | 150,000 | 688,185 (2%) | 0% | - | Common Stock | |
| Lifecore Biomedical Inc | Paul Josephs | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.19 per share. | 08 Jul 2025 | 54,857 | 633,328 (2%) | 0% | 8.2 | 449,279 | Common Stock |
| Lifecore Biomedical Inc | Paul Josephs | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.63 per share. | 20 May 2025 | 21,532 | 538,185 (1%) | 0% | 6.6 | 142,757 | Common Stock |
| Lifecore Biomedical Inc | Paul Josephs | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 5.74 per share. | 08 Jan 2025 | 17,000 | 559,717 (1%) | 0% | 5.7 | 97,580 | Common Stock |
| Lifecore Biomedical Inc | Paul Josephs | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Dec 2024 | 38,461 | 554,486 (1%) | 0% | 0 | Common Stock | |
| Lifecore Biomedical Inc | Paul Josephs | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.15 per share. | 06 Dec 2024 | 11,769 | 542,717 (1%) | 0% | 7.1 | 84,148 | Common Stock |
| Lifecore Biomedical Inc | Paul Josephs | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 May 2024 | 1,500,000 | 0 | - | - | Performance-Based Restricted Stock Units | |
| Lifecore Biomedical Inc | Paul Josephs | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 May 2024 | 525,000 | 525,000 (1%) | 1% | - | Common Stock | |
| Lifecore Biomedical Inc | Paul Josephs | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 20 May 2024 | 8,975 | 516,025 (1%) | 0% | - | Common Stock |